|Day Low/High||110.07 / 115.50|
|52 Wk Low/High||93.05 / 128.39|
Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she teams up with Celgene Corporation (NASDAQ:CELG) and...
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Celgene Corp. has taken over the #29 spot from Honeywell International Inc , according to ETF Channel.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
There's a lot out there to cheer investors, Cramer says, and August could turn out to be a better month than usual.
The bifurcation can be seen just by looking at Apple's recent results.
The company also could look to acquire a smaller biotech company, though likely not Medivation.
That may be the best way to get through the notorious month of August.
The biotech sector was a great short throughout the year, but that trade appears to be over, Cramer said.
Celgene (CELG) stock is down in pre-market trading amid allegations that it donated to charities as part of a scheme for billions of taxpayers' money.
Celgene's bullish action is leaving behind a solid foundation from which the stock can mount a new bull leg.
The company's hepatitis C drug division is expected to see losses in the second half of the year.
Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.
Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
Trade-Ideas LLC identified Celgene (CELG) as a pre-market leader candidate
Celgene (CELG) stock is trading higher pre-market after reporting its 2016 second quarter financial results.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period in 2015.